Stanford

Fangdi Sun

Assistant Professor of Medicine (Oncology)

Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

  900 Blake Wilbur Dr

  3rd Fl

  Stanford, CA 94305

  Tel (650) 498-6000 **Fax** (650) 724-1445

Bio

BIO

Dr. Sun is a medical oncologist and clinical investigator at Stanford University. She specializes in the treatment of patients with head and neck malignancies, with specific interests in virus-driven malignancies and novel, biomarker-guided therapies in head and neck cancer. She received her medical degree from Harvard Medical School, followed by a residency and chief residency at the University of California, San Francisco, and then served as chief fellow in hematology and medical oncology at Stanford University. She has earned honors and recognition from the American Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and International Association for the Study of Lung Cancer (IASLC), among other organizations.

CLINICAL FOCUS

- Head and Neck Neoplasms
- Medical Oncology

ACADEMIC APPOINTMENTS

- Assistant Professor-Univ Med Line, Medicine - Oncology

HONORS AND AWARDS

- Methods in Clinical Cancer Research Workshop, ASCO/AACR (2025)
- Targeted Therapies of Lung Cancer Education Award, IASLC (2024, 2025)
- Phi Beta Kappa, Phi Beta Kappa (2014)
- Burchard Scholar, MIT School of Humanities, Arts, and Social Sciences (2013)
- Tau Beta Pi Engineering Honor Society, Tau Beta Pi (2012)
- National Ocean Scholar, National Oceanic and Atmospheric Association (NOAA) (2010)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, Head & Neck General Committee, NRG Oncology (2026 - present)

- Member, Head & Neck Committee, ECOG-ACRIN (2025 - present)
- Member, Association of Northern California Oncologists (ANCO) (2022 - present)
- Member, American Society of Clinical Oncology (ASCO) (2022 - present)

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2025)
- Board Certification: Hematology, American Board of Internal Medicine (2024)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2021)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2025) CA
- Chief Residency, University of California, San Francisco , Internal Medicine
- Residency, University of California, San Francisco , Internal Medicine
- MD, Harvard Medical School
- BS, Massachusetts Institute of Technology , Biological Engineering

Publications

PUBLICATIONS

- **Antibiotic Use and Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma.** *Head & neck*
  Wu, S. S., Divi, V., Sunwoo, J. B., Jetly, A., Sun, F., Colevas, A. D., Holsinger, F. C., Lee, J., Finegersh, A., Baik, F., Chen, M. M.
  2026
- **Clinico-Genomic Characteristics and Treatment Outcomes of Patients with Advanced ALK-Rearranged Squamous and Adenosquamous Non-Small Cell Lung Cancers**
  Miao, E. A., Yeap, B., Daher, S., Lomibao, M., Sun, F., Keogh, R., Lambden, J., Reyes, A., Peterson, J. L., Liang, J., Liu, A., Do, A., Lee, et al
  ELSEVIER SCIENCE INC.2026: S7-S8
- **Accessibility of study contact information in ClinicalTrials.gov: A comprehensive analysis.**
  Sun, F., Colevas, A.
  LIPPINCOTT WILLIAMS & WILKINS.2026
- **Leptomeningeal disease in ALK-positive NSCLC: Survival impact of third-generation ALK inhibitors**
  Pan, K., Zheng, M., Xia, Y., Zhang, Y., Sun, F., Borgeaud, M., Singhal, S., Hong, L., Zhang, J., Li, W., Riess, J. W., Heymach, J. V., Myall, et al
  LIPPINCOTT WILLIAMS & WILKINS.2026
- **Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK-Rearranged Squamous and Adenosquamous Non-Small Cell Lung Cancers.** *JCO precision oncology*
  Miao, E. A., Yeap, B., Daher, S., Lomibao, M., Sun, F., Keogh, R., Lambden, J., Reyes, A., Peterson, J. L., Liang, J., Liu, A., Do, A., Lee, et al
  2026; 10 (3): e2501148
- **Leptomeningeal Disease in ALK-positive NSCLC: Survival Impact of Third-Generation ALK Inhibitors** *SNO/ASCO CNS Metastases Conference*
  Pan, K., Zheng, M., Xia, Y., Tan, A., Sun, F., Borgeaud, M., Singhal, S., Hong, L., Zhang, J., Li, W., Riess, J., Heymach, J., Myall, et al
  2026
- **PP01.06: Clinico-Genomic Characteristics and Treatment Outcomes of Patients with Advanced ALK-Rearranged Squamous and Adenosquamous Non-Small Cell Lung Cancers**
  Miao, E. A., Yeap, B., Daher, S., Lomibao, M., Sun, F., Keogh, R., Lambden, J., Reyes, A., Peterson, J. L., Liang, J., Liu, A., Do, A., Lee, et al
  2026: 104005
- **Timing of Concurrent Weekly Cisplatin with Radiation in the Definitive and Adjuvant Settings for Head and Neck Cancer–Is it Time to Re-Examine Our Guidelines?** *Multidisciplinary Head and Neck Cancers Symposium*
  Sun, F., Colevas, A. D.
  2026: e64

- **Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC A Multicenter Retrospective Study** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Waliany, S., Roy, S., Pecci, F., Weber, U. M., Sun, F., Arter, Z., Lomibao, M., V. Alessi, J., Nishino, M., Luo, F., Repetto, M., Falcon, C., Do, et al
  2025; 23 (12)
- **Cisplatin, immunotherapy, and chemoradiation in nasopharyngeal carcinoma: How far should one trial move the needle?** *Med (New York, N.Y.)*
  Sun, F., Colevas, A. D.
  2025; 6 (11): 100917
- **Characteristics of Short-Term Survivors With ALK or ROS1-Altered Metastatic NSCLC.** *JTO clinical and research reports*
  Liu, K. L., Watts, A., Grady, C. B., Liu, G., Patel, D., Balaratnam, K., Liu, S. V., Montenegro, G. B., Nie, Y., Nieva, J., Herrmann, A., Marrone, K., Lam, et al
  2025; 6 (11): 100876
- **The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study.** *Annals of oncology : official journal of the European Society for Medical Oncology*
  Zheng, M. M., Xia, Y., Pan, K., Sun, F., Tan, A. C., Dong, X. R., Tu, H. Y., Tang, L. B., Li, Y. S., Yin, K., Borgeaud, M., Singhal, S., Zhu, et al
  2025
- **Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*
  Sun, F., Banwait, M. K., Singhal, S., Herrmann, A., Piotrowska, Z., Yun, K., Bazhenova, L., Ullah, A. T., Guo, E. W., Wakelee, H. A., Neal, J. W., Das, M. S., Ramchandran, et al
  2025; 208: 108747
- **Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer.** *Journal for immunotherapy of cancer*
  Miller, N. J., Baik, C., Neal, J. W., Sun, F., Santana-Davila, R., Lee, S., Eaton, K. D., Martins, R. G., Rodriguez, C., Wakelee, H., Padda, S. K., Sotillo, E., Konnick, et al
  2025; 13 (7)
- **FLAURA2: evidence for escalated first-line therapy in EGFR-mutated non-small cell lung cancer with central nervous system metastases.** *Translational cancer research*
  Sun, F., Neal, J. W., Myall, N. J.
  2025; 14 (6): 3295-3301
- **Update: Immunotherapeutic Strategies in HPV-Associated Head and Neck Squamous Cell Carcinoma.** *Viruses*
  Sun, F., Colevas, A. D.
  2025; 17 (5)
- **Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis.** *Lung cancer (Amsterdam, Netherlands)*
  Barsouk, A., Elghawy, O., Watts, A., Reed-Guy, L., Tompkins, W., Chandrasekhara, K., Grady, C. B., Iams, W., Sun, F., Liu, G., Patel, D., Nieva, J. J., Marrone, et al
  2025; 203: 108551
- **Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis.** *JTO clinical and research reports*
  Stalker, M., Grady, C. B., Watts, A., Hwang, W. T., Chandrasekhara, K., Sun, F., Liu, G., Patel, D., Nieva, J., Herrmann, A., Marrone, K., Lam, V. K., Velcheti, et al
  2025; 6 (1): 100765
- **Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer** *Clinical Lung Cancer*
  Sun, F., Nagpal, S., Singhal, S., Neal, J. W., Wakelee, H. A., Myall, N. J., Bolan, P., Riess, J. W., Gandara, D. R., Das, M. S.
  2025; 26 (7): 603-609.e2
- **A summary of the 2025 lung cancer summit at Stanford University: understanding lung cancer in people who have never smoked** *Journal of Asian Health*
  Sun, F., Lin, B., Wakelee, H. A.

2025; 5 (2)

- **Recent updates in targeted therapy for advanced non-small cell lung cancer with actionable genomic alterations: a narrative review** *AME Clinical Trials Review*
  Sun, F., Neal, J. W.
  2025; 3

- **Highly CNS-penetrant tyrosine kinase inhibitors improve leptomeningeal overall survival in NSCLC patients with leptomeningeal disease** *AACR Annual Meeting*
  Le, X., Pan, K., Zhang, J., Sun, F., Borgeaud, M., Riess, J., Myall, N., Xia, Y., Addeo, A., Heymach, J.
  2025: 1155

- **Targeting the EZH2-SLFN11 pathway-a lesson in developing molecularly-informed treatments for recurrent small cell lung cancer.** *Translational cancer research*
  Sun, F., Das, M. S.
  2024; 13 (12): 6608-6612

- **Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer.** *Pharmacoepidemiology and drug safety*
  Grady, C. B., Hwang, W. T., Reuss, J. E., Iams, W., Cass, A., Liu, G., Patel, D., Liu, S. V., Montenegro, G. L., Patil, T., Nieva, J. J., Herrmann, A., Marrone, et al
  2024; 33 (12): e70049

- **Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC.** *JTO clinical and research reports*
  Tompkins, W., Grady, C. B., Hwang, W. T., Chandrasekhara, K., McCoach, C., Sun, F., Liu, G., Patel, D., Nieva, J., Herrmann, A., Marrone, K., Lam, V. K., Velcheti, et al
  2024; 5 (8): 100669

- **Combination metronomic chemotherapy and immunotherapy in non-small cell lung cancer remains exploratory: the VinMetAtezo trial** *AME Clinical Trials Review*
  Sun, F., Neal, J. W.
  2024; 2 (12)

- **Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC)**
  Marmarelis, M., Grady, C. B., McCoach, C., Sun, F., Liu, G., Patel, D., Nieva, J. J., Marrone, K. A., Velcheti, V., Liu, S. V., Patil, T., Weiss, J., Schwartzman, et al
  LIPPINCOTT WILLIAMS & WILKINS.2023

- **Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung.** *JCO precision oncology*
  Sun, F., Grenert, J. P., Tan, L., Van Ziffle, J., Joseph, N. M., Mulvey, C. K., Bergsland, E.
  2022; 6: e2200009

- **DESIGN, IMPLEMENTATION, AND EVALUATION OF A NOVEL CLINICAL ROLE TO ADDRESS WORK HOUR VIOLATIONS IN REAL TIME**
  Penner, J., Berman, R., Caughron, H., Chia, D., DeGette, R., Flynn, S. J., Goglin, A., Martinez, A., Monash, B., Santhosh, L., Sun, F., Wheeler, D., Thomas, et al
  SPRINGER.2022: S616-S617

- **In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
  Thomas, N. J., Myall, N. J., Sun, F., Patil, T., Mushtaq, R., Yu, C., Sinha, S., Pollom, E. L., Nagpal, S., Camidge, D. R., Rusthoven, C. G., Braunstein, S. E., Wakelee, et al
  1800; 17 (2): e12-e14

- **Capturing what matters: A retrospective observational study of advance care planning documentation at an academic medical center during the COVID-19 pandemic.** *Palliative medicine*
  Sun, F., Lipinsky DeGette, R., Cummings, E. C., Deng, L. X., Hauser, K. A., Kopp, Z., Penner, J. C., Scott, B. S., Raffel, K. E., Kantor, M. A.
  2022; 36 (2): 342-347

- **Treatment patterns and outcomes in ALK or ROS1 altered NSCLC: An ATOMIC Registry Study** *ASCO Annual Meeting*
  Marmarelis, M. E., Grady, C. B., Liu, G., Patel, D., Liu, S. V., Montenegro, G. L., Patil, T., Nieva, J. J., Herrmann, A., Marrone, K., Lam, V. K., Sun, F., Dowell, et al
  2022

- **Brain Metastases in EGFR- and ALK-positive Non-Small Cell Lung Cancer: Outcomes of CNS Penetrant Tyrosine Kinase Inhibitors (TKIs) Alone versus in Combination with Radiation.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
  Thomas, N. J., Myall, N. J., Sun, F., Patil, T., Mushtaq, R., Yu, C., Sinha, S., Pollom, E. L., Nagpal, S., Camidge, D. R., Rusthoven, C. G., Braunstein, S. E., Wakelee, et al
  2021

- **Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.** *Current treatment options in oncology*
  Sun, F., McCoach, C. E.
  2021; 22 (8): 72

- **Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer.** *Breast cancer research and treatment*
  Daniell, K. M., Bardia, A., Sun, F., Roberts, S. A., Brunelle, C. L., Gillespie, T. C., Sayegh, H. E., Naoum, G. E., Juric, D., Isakoff, S. J., Fitzgerald, D. M., Taghian, A. G.
  2019; 175 (3): 649-658

- **Upper extremity edema in the at-risk arm among patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer** *San Antonio Breast Cancer Symposium*
  Daniell, K. M., Bardia, A., Sun, F., Brunelle, C. L., Gillespie, T. C., Sayegh, H. E., Naoum, G. E., Isakoff, S. J., Juric, D., Taghian, A. G.
  2019

- **Perometry versus simulated circumferential tape measurement for the detection of breast cancer-related lymphedema.** *Breast cancer research and treatment*
  Sun, F., Hall, A., Tighe, M. P., Brunelle, C. L., Sayegh, H. E., Gillespie, T. C., Daniell, K. M., Taghian, A. G.
  2018; 172 (1): 83-91

- **Letter to the editor of "Current and future perspectives on the evaluation, prevention and conservative management of breast cancer related lymphoedema: A best practice guideline" from N. Gebruers and colleagues.** *European journal of obstetrics, gynecology, and reproductive biology*
  Sun, F., Brunelle, C. L., Daniell, K. M., Gillespie, T. C., Sayegh, H. E., Taghian, A. G.
  2018; 225: 255-256

- **Amino Acid Uptake Measured by [18F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas.** *Theranostics*
  Prudner, B. C., Sun, F., Kremer, J. C., Xu, J., Huang, C., Sai, K. K., Morgan, Z., Leeds, H., McConathy, J., Van Tine, B. A.
  2018; 8 (8): 2107-2116

- **Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding proteins.** *Nucleic acids research*
  Yang, N. J., Kauke, M. J., Sun, F., Yang, L. F., Maass, K. F., Traxlmayr, M. W., Yu, Y., Xu, Y., Langer, R. S., Anderson, D. G., Wittrup, K. D.
  2017; 45 (13): 7602-7614

- **The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema.** *Breast cancer research and treatment*
  Sun, F., Skolny, M. N., Swaroop, M. N., Rawal, B., Catalano, P. J., Brunelle, C. L., Miller, C. L., Taghian, A. G.
  2016; 157 (2): 229-240

- **Risk Factors For Mortality In Critically Ill Patients Requiring New Renal Replacement Therapy**
  Sun, F., Cui, A., Lokhandwala, S., Tyler, P., Shen, M., Paul, D., Pollard, T.
  AMER THORACIC SOC.2016